Skip to content

Press

Events
Bioluminescence to participate in panel “Surviving Turbulence: Extending Runway and Creating Value in Healthcare and Biotech” at BIO International Convention 2024
June 4, 2024 Jun 4, 2024 San Diego, California
Portfolio-Press Releases
ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of Its Board of Directors
May 13, 2024 May 13, 2024
Portfolio-Press Releases
Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer
May 13, 2024 May 13, 2024
Portfolio-Press Releases
Cerevance Achieves First Milestone in Research Collaboration with Merck
May 2, 2024 May 2, 2024
Portfolio-Press Releases
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
April 25, 2024 Apr 25, 2024
Portfolio-Media Coverage
Intellia and Recode collaborate on genomic medicines for cystic fibrosis
February 16, 2024 Feb 16, 2024 BioWorld
Portfolio-Media Coverage
Intellia Therapeutics, ReCode Therapeutics to collaborate on genomic medicines for CF
February 16, 2024 Feb 16, 2024 LabPulse
Portfolio-Media Coverage
Intellia, ReCode team up to develop gene-editing therapies for CF
February 16, 2024 Feb 16, 2024 Cystic Fibrosis News Today
Portfolio-Media Coverage
Intellia and ReCode join forces on cystic fibrosis gene therapy
February 15, 2024 Feb 15, 2024 Investing.com
Portfolio-Media Coverage
Intellia and ReCode Join Forces to Revolutionize Cystic Fibrosis Treatment with CRISPR Gene-Editing
February 15, 2024 Feb 15, 2024 BNN